Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Class Definition - The lawsuit aims to recover losses for investors adversely affected by the alleged fraud, specifically those who acquired Zenas BioPharma securities linked to the IPO registration statement and prospectus [2]. Case Details - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to public statements that were false and misleading [3]. Next Steps - Investors who suffered losses in Zenas BioPharma have until June 16, 2025, to request appointment as lead plaintiff, with no costs or obligations to participate in the lawsuit [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].